After years of anticipation and encouraging responses to pathfinder products, monoclonal antibodies are now set to realise their true clinical and commercial potential. But what are the prospects for the products that will lead the market? This new management report covers 30 leading compounds and is essential reading for everyone working in the field. After years of anticipation and encouraging responses to pathfinder products, monoclonal antibodies are now set to realise their true clinical and commercial potential. But what are the prospects for the products that will lead the market?

The position of monoclonal antibodies on the market is solidly poised for growth with six novel therapies expected to launch within the next five years. The ability to be an effective medicine puts antibodies, and the companies having a hand in their development, into a position to create new markets. Buoyed by ticilimumab and ipilimumab, the treatment of melanoma will be among the first to follow the current blockbuster successes in breast cancer and leukaemia. Companies with pipelines to sell or in development, such as Genmab, Immunomedics and Seattle Genetics, have attracted capital from large pharmaceutical companies and investors.

HUGE POTENTIAL
While large pharma companies predictably take aim at the largest treatable populations (breast cancer, colorectal disease, NHL, leukaemia), there is an abundance of niches for monoclonal antibody therapy applications and a staggering number of potential disease targets. Smaller developer companies are likely to become more visible as their products move closer to regulatory approval.

That is why this new management report is essential for everyone working in the field. The report covers over 30 leading compounds originating from the largest blue-chip multinationals to smaller developer companies.

KEY EVALUATION FOR EACH PRODUCT
It is vital that new compounds can be seen in the wider competitive/development landscape. For that reason we have established a unique competitor analysis based on each of the following criteria:

Novelty/rationale for mechanism of action;
Proof of concept/clinical data;
Management/clinical expertise;
Competition within the marketplace;
Risks associated with developing a drug within a therapeutic class

ANTICANCER PRODUCTS

ACA 125, VaccinOvar
Cell Control Biomedical

adecatumumab
Micromet/Merck KGaA

Antibody 3F8
MSKCC

BrevaRex
Virexx & Unither

catumaxomab
Fresius Biotech/TRION Pharma

CNT0328
Centocor

Cotara
Peregrine Pharma

daclizumab
PDL BioPharma/Roche

epratuzumab Immunomedics

ertumaxomab
Fresius Biotech/TRION Pharma

HA20/IMMV-106
Immunomedics

HuMax-EGFr
Genmab

galiximab
Biogen Idec

HuN901-BM1
ImmunoGen
ipilimumab
Bristol-Myers Squibb

KW-2871
Kyowa Pharmaceutical

lumiliximab
Biogen Idec

matuzumab
EMD Pharma/Merck/Takeda

MDX-060
Medarex

Abegrin
MedImmune

ofatumumab
Genmab

oregovomab
Virexx & Unither

Rencarex
Wilex Centocor

SGN-30
Seattle Genetics

ticilimumab
Pfizer/Amgen

volociximab
PDL BioPharma

zanolimumab
Genmab/Merck KGaA

RHEUMATOLOGY PRODUCTS

belimumab
Human Genome Sciences/GSK

certolizumab pegol
UCB

golimumab
Centocor/Schering Plough
tocilizumab
Chugai/Roche

HuMax CD-20
Genmab

About the Author
Barbara Nasto is an independent consultant with over 13 years experience writing about biotechnology with an emphasis on monoclonal antibody therapeutics. Following a short interlude in academic research, she entered into the science publishing industry working for the prestigious Nature Publishing Group (New York, NY) where she published articles and reports in journals such as Nature Biotechnology and Nature Medicine. She later served as Editor for Helix, Amgen's Journal of Biotechnology, published by Excerpta Medica while continuing to publish articles on the biotechnology industry.

In 2004, Barbara Nasto started a consulting business to provide independent, tailor-made, research to pharmaceutical companies and business publications.